Publications

Detailed Information

Risk Factors of Drug Interaction between Warfarin and Nonsteroidal Anti-Inflammatory Drugs in Practical Setting

DC Field Value Language
dc.contributor.authorChoi, Kyung Hee-
dc.contributor.authorKim, Ah Jeong-
dc.contributor.authorSon, In Ja-
dc.contributor.authorKim, Kyung-Hwan-
dc.contributor.authorAhn, Hyuk-
dc.contributor.authorLee, Eun Bong-
dc.contributor.authorKim, Ki-Bong-
dc.date.accessioned2012-05-29T05:51:31Z-
dc.date.available2012-05-29T05:51:31Z-
dc.date.issued2010-03-
dc.identifier.citationJOURNAL OF KOREAN MEDICAL SCIENCE; Vol.25 3; 337-341ko_KR
dc.identifier.issn1011-8934-
dc.identifier.urihttps://hdl.handle.net/10371/76541-
dc.description.abstractNonsteroidal anti-inflammatory drugs (NSAIDs) are known to interact with the oral anticoagulant warfarin and can cause a serious bleeding complication. In this study, we evaluated the risk factors for international normalized ratio (INR) increase, which is a surrogate marker of bleeding, after addition of an NSAID in a total of 98 patients who used warfarin. Patient age, sex, body mass index, maintenance warfarin dose, baseline INR, coadministered medications, underlying diseases, and liver and kidney functions were evaluated for possible risk factors with INR increase >= 15.0% as the primary end-point. Of the 98 patients, 39 (39.8%) showed an INR elevation of >= 15.0% after adding a NSAID to warfarin therapy. Multivariate analysis showed that high maintenance dose (>40 mg/week) of warfarin (P=0.001), the presence of coadministered medications (P=0.024), the use of meloxicam (P=0.025) and low baseline INR value (P=0.03) were the risk factors for INR increase in respect to NSAID-warfarin interaction. In conclusion, special caution is required when an NSAID is administered to warfarin users if patients are taking warfarin >40 mg/week and other medications interacting with warfarin.ko_KR
dc.language.isoenko_KR
dc.publisherKOREAN ACAD MEDICAL SCIENCESko_KR
dc.subjectWarfarinko_KR
dc.subjectAnti-Inflammatory Agentsko_KR
dc.subjectNon-Steroidalko_KR
dc.subjectDrug Interactionsko_KR
dc.titleRisk Factors of Drug Interaction between Warfarin and Nonsteroidal Anti-Inflammatory Drugs in Practical Settingko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor최경희-
dc.contributor.AlternativeAuthor김아정-
dc.contributor.AlternativeAuthor손인자-
dc.contributor.AlternativeAuthor김경환-
dc.contributor.AlternativeAuthor김기봉-
dc.contributor.AlternativeAuthor안혁-
dc.contributor.AlternativeAuthor이은봉-
dc.identifier.doi10.3346/jkms.2010.25.3.337-
dc.citation.journaltitleJOURNAL OF KOREAN MEDICAL SCIENCE-
dc.description.citedreferenceShen AYJ, 2007, J AM COLL CARDIOL, V50, P309, DOI 10.1016/j.jacc.2007.01.098-
dc.description.citedreferenceSchauer DP, 2007, AM J MED SCI, V333, P67-
dc.description.citedreferenceHekselman I, 2007, ISRAEL MED ASSOC J, V9, P12-
dc.description.citedreferenceHeneghan C, 2006, LANCET, V367, P404-
dc.description.citedreferenceWIVANITKIT V, 2006, CLIN APPL THROMB-HEM, V12, P219-
dc.description.citedreferenceBAXTER K, 2006, STOCKELYS DRUG INTER, P255-
dc.description.citedreferenceSconce EA, 2005, BLOOD, V106, P2329, DOI 10.1182/blood-2005-03-1108-
dc.description.citedreferenceRieder MJ, 2005, NEW ENGL J MED, V352, P2285-
dc.description.citedreferenceMalhi H, 2004, POSTGRAD MED J, V80, P107, DOI 10.1136/pmj.2003.006478-
dc.description.citedreferencevan Dijk KN, 2004, THROMB HAEMOSTASIS, V91, P95, DOI 10.1160/TH03-05-0325-
dc.description.citedreferenceSchaefer MG, 2003, AM J HEALTH-SYST PH, V60, P1319-
dc.description.citedreferenceBlann AD, 2003, BRIT MED J, V326, P153-
dc.description.citedreferenceKnijff-Dutmer EAJ, 2003, ANN PHARMACOTHER, V37, P12-
dc.description.citedreferenceStading JA, 2001, AM J HEALTH-SYST PH, V58, P2076-
dc.description.citedreferenceSchwartz JI, 2000, CLIN PHARMACOL THER, V68, P626-
dc.description.citedreferenceHaase KK, 2000, ANN PHARMACOTHER, V34, P666-
dc.description.citedreferenceMersfelder TL, 2000, ANN PHARMACOTHER, V34, P325-
dc.description.citedreferenceThrift AG, 1999, BRIT MED J, V318, P759-
dc.description.citedreferenceChan TYK, 1997, BRIT J CLIN PRACT, V51, P177-
dc.description.citedreferenceTurck D, 1997, EUR J CLIN PHARMACOL, V51, P421-
dc.description.citedreferenceHarder S, 1996, CLIN PHARMACOKINET, V30, P416-
dc.description.citedreferenceBROUWERS JRBJ, 1994, CLIN PHARMACOKINET, V27, P462-
dc.description.citedreferenceWELLS PS, 1994, ANN INTERN MED, V121, P676-
dc.description.citedreferenceVANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557-
dc.description.citedreferenceWILLIAMS RL, 1976, CLIN PHARMACOL THER, V20, P90-
dc.description.tc1-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share